PDE5A and breast cancer: More relevantly, treatment with the CXCL16 neutralizing antibody was able to significantly abolish the stimulatory effects exerted by CM derived from PDE5-overexpressing MEFs on both growth and motility of MCF-7 breast cancer cells (Figure 5H).